

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Singular Health Group Limited
<b>ABN</b>	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Howard Digby
<b>Date of last notice</b>	13 February 2025

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	(1) Indirect (2) Direct (3) Direct
<b>Nature of indirect interest (including registered holder)</b>	(1) (1) LAMMA NOMINEES PTY LTD <XL MIDDLETON A/C>, an entity controlled by Mr Digby, of which he is a beneficiary (2) N/A (3) N/A
<b>Date of change</b>	15 April 2025
<b>No. of securities held prior to change</b>	(1) 35,000 - ORDINARY FULLY PAID SHARES (2.1) 1,250,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (2.2) NIL - UNLISTED OPTIONS @ \$0.25 EXP 15/04/2028 (3) 645,609 - ORDINARY FULLY PAID SHARES
<b>Class</b>	(2.2) UNLISTED OPTIONS @ \$0.25 EXP 15/04/2028
<b>Number acquired</b>	(2.2) 1,000,000 - UNLISTED OPTIONS @ \$0.25 EXP 15/04/2028
<b>Number disposed</b>	NIL
<b>Value/Consideration</b>	Issued as part of Non-executive Director Remuneration Package. Refer Notice of Meeting lodged ASX on 17 February 2025 for further detail.
<b>No. of securities held after change</b>	(1) 35,000 - ORDINARY FULLY PAID SHARES (2.1) 1,250,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (2.2) 1,000,000 - UNLISTED OPTIONS @ \$0.25 EXP 15/04/2028 (3) 645,609 - ORDINARY FULLY PAID SHARES

<sup>+</sup> See [chapter 19](#) for defined terms.

<b>Nature of change</b>	Allotment of unlisted options subject to vesting conditions, as approved by shareholders at General Meeting held 19 March 2025.
-------------------------	---------------------------------------------------------------------------------------------------------------------------------

## Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b>	N/A
<b>Interest after change</b>	N/A

## Part 3 - <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No.
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See [chapter 19](#) for defined terms.

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Singular Health Group Limited
<b>ABN</b>	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Denning Chong
<b>Date of last notice</b>	13 February 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b>	1) JCC HEALTH PTY LTD <THE JDE MEDVDR A/C> - An entity controlled by Mr Chong, and of which he is a beneficiary  (2) JDE CAPITAL PTY LTD <JDE CAPITAL A/C> - An entity controlled by Mr Chong, and of which he is a beneficiary  (3) MAXWELL STANLEY CAPITAL PTY LTD <Maxwell Stanley Capital A/C> - an entity controlled by Mr Chong and of which he is a beneficiary
<b>Date of change</b>	15 April 2025

<sup>+</sup> See [chapter 19](#) for defined terms.

<b>No. of securities held prior to change</b>	<p>(1.1) 6,640,869 - ORDINARY FULLY PAID SHARES</p> <p>(1.2) 1,250,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027</p> <p>(1.3) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028</p> <p>(2.1) 6,667,706 - ORDINARY FULLY PAID SHARES</p> <p>(2.2) 1,818,182 - UNLISTED OPTIONS @ \$0.10 EXP 26/06/2026</p> <p>(2.3) 10,000,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027</p> <p>(2.4) 500,000 - PERFORMANCE RIGHTS - TRANCHE B</p> <p>(2.5) 1,500,000 - PERFORMANCE RIGHTS EXP 8/12/2027</p> <p>(2.6) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028</p> <p>(3) NIL - UNLISTED OPTIONS @ \$0.25 EXP 15/04/2029</p>
<b>Class</b>	(3) UNLISTED OPTIONS @ \$0.25 EXP 15/04/2029
<b>Number acquired</b>	(3) 10,000,000 - UNLISTED OPTIONS @ \$0.25 EXP 15/04/2029
<b>Number disposed</b>	NIL
<b>Value/Consideration</b>	Issued as part of LTIP for Managing Director. Refer Notice of Meeting lodged ASX 17 February 2025 for further detail.
<b>No. of securities held after change</b>	<p>(1.1) 6,640,869 - ORDINARY FULLY PAID SHARES</p> <p>(1.2) 1,250,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027</p> <p>(1.3) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028</p> <p>(2.1) 1,500,000 - ORDINARY FULLY PAID SHARES</p> <p>(2.2) 6,667,706 - UNLISTED OPTIONS @ \$0.10 EXP 26/06/2026</p> <p>(2.3) 10,000,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027</p> <p>(2.4) 500,000 - PERFORMANCE RIGHTS - TRANCHE B</p> <p>(2.5) 1,500,000 - PERFORMANCE RIGHTS EXP 8/12/2027</p> <p>(2.6) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028</p> <p>(3) 10,000,000 - UNLISTED OPTIONS @ \$0.25 EXP 15/04/2029</p>

<sup>+</sup> See [chapter 19](#) for defined terms.

For personal use only

<b>Nature of change</b>	Allotment of unlisted options subject to vesting conditions, as approved by shareholders at General Meeting held 19 March 2025.
-------------------------	---------------------------------------------------------------------------------------------------------------------------------

## Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b>	N/A
<b>Interest after change</b>	N/A

## Part 3 - <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See [chapter 19](#) for defined terms.

For personal use only

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Singular Health Group Limited
<b>ABN</b>	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	Andrew Just
<b>Date of last notice</b>	13 February 2025

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b>	N/A
<b>Date of change</b>	15 April 2025
<b>No. of securities held prior to change</b>	(1) 336,364 - ORDINARY FULLY PAID SHARES (2) 1,000,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (3) NIL - UNLISTED OPTIONS @ \$0.25 EXP 15/04/2028
<b>Class</b>	(1) ORDINARY FULLY PAID SHARES (2) UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (3) UNLISTED OPTIONS @ \$0.25 EXP 15/04/2028
<b>Number acquired</b>	(3) 1,000,000 - UNLISTED OPTIONS @ \$0.25 EXP 15/04/2028
<b>Number disposed</b>	NIL
<b>Value/Consideration</b>	Issued as part of Non-executive Director Remuneration Package. Refer Notice of Meeting lodged ASX on 17 February 2025 for further detail.
<b>No. of securities held after change</b>	(1) 336,364 - ORDINARY FULLY PAID SHARES (2) 1,000,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (3) 1,000,000 - UNLISTED OPTIONS @ \$0.25 EXP 15/04/2028
<b>Nature of change</b>	Allotment of unlisted options subject to vesting conditions, as approved by shareholders at General Meeting held 19 March 2025.

### Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be

<sup>+</sup> See [chapter 19](#) for defined terms.

disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b>	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b>	N/A
<b>Interest after change</b>	N/A

**Part 3 - <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See [chapter 19](#) for defined terms.  
01/01/2011 Appendix 3Y Page 2

For personal use only